Effect of Genetic Polymorphisms on Alzheimer's Disease Treatment Outcomes: an Update

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2019 Apr 18

PMID 30992661

Citations 7

Authors

Riyadi Sumirtanurdin

Amirah Y Thalib

Kelvin Cantona

Rizky Abdulah

Affiliations

Soon will be listed here.

Abstract

Genetic variations in individuals may cause differences in the response to cholinesterase inhibitor drugs used in the treatment of Alzheimer's disease (AD). Through this review, we aimed to understand the potential relationship between genetic polymorphisms and treatment response in AD. We conducted a systematic review of the studies published from 2006 to 2018 that assessed the relationship between genetic polymorphisms and the pharmacotherapeutic outcomes of patients with AD. Via several possible mechanisms, genetic polymorphisms of many genes, including , , , , , and , appear to have strong correlations with the treatment response of patients with AD. Indeed, these genetic polymorphisms, either in the form of single nucleotide polymorphisms or direct changes to one or more amino acids, have been shown to cause differences in the therapeutic response. In summary, our findings indicate that genetic polymorphisms should be considered in the management of AD to achieve both effective and efficient treatment outcomes in terms of cost and prognosis.

Citing Articles

Exploring the Efficacy and Target Genes of Against Alzheimer's Disease Based on Multi-Omics, Computational Chemistry, and Experimental Verification.

Zheng Y, Gao X, Tang J, Gao L, Cui X, Liu K Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996839 PMC: 11853862. DOI: 10.3390/cimb47020118.

Comparing ATPase activity of ATP-binding cassette subfamily C member 4, lamprey CFTR, and human CFTR using an antimony-phosphomolybdate assay.

Cui G, Strickland K, Vazquez Cegla A, McCarty N Front Pharmacol. 2024; 15:1363456.

PMID: 38440176 PMC: 10910009. DOI: 10.3389/fphar.2024.1363456.

Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond.

Garmendia J, De Sanctis C, Das V, Annadurai N, Hajduch M, De Sanctis J Curr Neuropharmacol. 2023; 22(6):1080-1109.

PMID: 37898823 PMC: 10964103. DOI: 10.2174/1570159X22666231017141636.

Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Pozzi F, Conti E, Appollonio I, Ferrarese C, Tremolizzo L Front Neurosci. 2022; 16:998224.

PMID: 36203811 PMC: 9530658. DOI: 10.3389/fnins.2022.998224.

Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family.

Tejada Moreno J, Villegas Lanau A, Madrigal Zapata L, Baena Pineda A, Velez Hernandez J, Campo Nieto O PLoS One. 2022; 17(7):e0269955.

PMID: 35905044 PMC: 9337667. DOI: 10.1371/journal.pone.0269955.

References

Owe-Larsson B, Berglund M, Kristensson K, Garoff H, Larhammar D, Brodin L . Perturbation of the synaptic release machinery in hippocampal neurons by overexpression of SNAP-25 with the Semliki Forest virus vector. Eur J Neurosci. 1999; 11(6):1981-7. DOI: 10.1046/j.1460-9568.1999.00614.x. View

Brunger A . Structural insights into the molecular mechanism of Ca(2+)-dependent exocytosis. Curr Opin Neurobiol. 2000; 10(3):293-302. DOI: 10.1016/s0959-4388(00)00098-2. View

Grehan S, Tse E, Taylor J . Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci. 2001; 21(3):812-22. PMC: 6762321. View

Osterlund M, Hurd Y . Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol. 2001; 64(3):251-67. DOI: 10.1016/s0301-0082(00)00059-9. View

White F, Nicoll J, Roses A, Horsburgh K . Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis. 2001; 8(4):611-25. DOI: 10.1006/nbdi.2001.0401. View

Mauch D, Nagler K, Schumacher S, Goritz C, Muller E, Otto A . CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001; 294(5545):1354-7. DOI: 10.1126/science.294.5545.1354. View

Teter B, Xu P, Gilbert J, Roses A, Galasko D, Cole G . Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. J Neurosci Res. 2002; 68(3):331-6. DOI: 10.1002/jnr.10221. View

Jann M, Shirley K, Small G . Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002; 41(10):719-39. DOI: 10.2165/00003088-200241100-00003. View

Getz G, Reardon C . Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol. 2004; 15(3):261-7. DOI: 10.1097/00041433-200406000-00005. View

10.

Ellis J . Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc. 2005; 105(3):145-58. View

11.

Pola R, Flex A, Ciaburri M, Rovella E, Valiani A, Reali G . Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene. Neurosci Lett. 2005; 382(3):338-41. DOI: 10.1016/j.neulet.2005.03.027. View

12.

Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, Katsuki H . Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol. 2005; 527(1-3):77-85. DOI: 10.1016/j.ejphar.2005.10.028. View

13.

Harold D, Macgregor S, Patterson C, Hollingworth P, Moore P, Owen M . A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease. Pharmacogenet Genomics. 2006; 16(2):75-7. DOI: 10.1097/01.fpc.0000189799.88596.04. View

14.

Mahley R, Weisgraber K, Huang Y . Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006; 103(15):5644-51. PMC: 1414631. DOI: 10.1073/pnas.0600549103. View

15.

Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley R, Huang Y . Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006; 26(19):4985-94. PMC: 6674234. DOI: 10.1523/JNEUROSCI.5476-05.2006. View

16.

Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A . Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. 2006; 51(3):474-86. DOI: 10.1016/j.neuropharm.2006.04.007. View

17.

Varsaldi F, Miglio G, Scordo M, Dahl M, Villa L, Biolcati A . Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 2006; 62(9):721-6. DOI: 10.1007/s00228-006-0168-1. View

18.

Blesa R, Aguilar M, Pena Casanova J, Boada M, Martinez S, Alom J . Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2006; 20(4):248-54. DOI: 10.1097/01.wad.0000213880.93665.c7. View

19.

Wonnacott S, Barik J, Dickinson J, Jones I . Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci. 2006; 30(1-2):137-40. DOI: 10.1385/JMN:30:1:137. View

20.

Pozzi D, Condliffe S, Bozzi Y, Chikhladze M, Grumelli C, Proux-Gillardeaux V . Activity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channels. Proc Natl Acad Sci U S A. 2007; 105(1):323-8. PMC: 2224210. DOI: 10.1073/pnas.0706211105. View